thalidomide has been researched along with Delayed Hypersensitivity in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide appears to be a safe and effective alternative for short-term healing in patients who develop infliximab-induced delayed hypersensitivity reaction and may be an alternative strategy for those at risk." | 6.70 | Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. ( Ehrenpreis, E; Kane, S; Stone, LJ, 2002) |
| "Thalidomide treatment was well tolerated, without serious adverse events." | 6.68 | Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. ( Akarasewi, P; Burroughs, M; Johnson, B; Kaplan, G; Klausner, JD; Makonkawkeyoon, S; Molloy, A; Rom, W; Tramontana, JM; Utaipat, U, 1995) |
| "Thalidomide appears to be a safe and effective alternative for short-term healing in patients who develop infliximab-induced delayed hypersensitivity reaction and may be an alternative strategy for those at risk." | 2.70 | Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series. ( Ehrenpreis, E; Kane, S; Stone, LJ, 2002) |
| "Thalidomide treatment was well tolerated, without serious adverse events." | 2.68 | Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. ( Akarasewi, P; Burroughs, M; Johnson, B; Kaplan, G; Klausner, JD; Makonkawkeyoon, S; Molloy, A; Rom, W; Tramontana, JM; Utaipat, U, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Grandoni, F | 1 |
| Stalder, G | 1 |
| Borgeat Kaeser, A | 1 |
| Ribi, C | 1 |
| Cairoli, A | 1 |
| Blum, S | 1 |
| Lee, MJ | 1 |
| Wickner, P | 1 |
| Fanning, L | 1 |
| Schlossman, R | 1 |
| Richardson, P | 1 |
| Laubach, J | 1 |
| Castells, M | 1 |
| Kane, S | 1 |
| Stone, LJ | 1 |
| Ehrenpreis, E | 1 |
| Rea, TH | 1 |
| Yoshida, T | 1 |
| Tramontana, JM | 1 |
| Utaipat, U | 1 |
| Molloy, A | 1 |
| Akarasewi, P | 1 |
| Burroughs, M | 1 |
| Makonkawkeyoon, S | 2 |
| Johnson, B | 1 |
| Klausner, JD | 2 |
| Rom, W | 1 |
| Kaplan, G | 2 |
| Naafs, B | 1 |
| Haslett, PA | 1 |
| Moreira, A | 1 |
| Metatratip, P | 1 |
| Boyle, B | 1 |
| Kunachiwa, W | 1 |
| Maneekarn, N | 1 |
| Vongchan, P | 1 |
| Corral, LG | 1 |
| Elbeik, T | 1 |
| Shen, Z | 1 |
| Descotes, J | 1 |
| Tedone, R | 1 |
| Evreux, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| Pharmacologic T Cell Costimulation In HIV Disease[NCT00053430] | Phase 2 | 40 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Delayed Hypersensitivity
| Article | Year |
|---|---|
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A | 1996 |
3 trials available for thalidomide and Delayed Hypersensitivity
| Article | Year |
|---|---|
Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series.
Topics: Adult; Antibodies, Monoclonal; Crohn Disease; Drug Hypersensitivity; Female; Follow-Up Studies; Huma | 2002 |
Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.
Topics: Adult; Aged; Cells, Cultured; Cytokines; Humans; Hypersensitivity, Delayed; Immunosuppressive Agents | 1995 |
Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hyperse | 1999 |
4 other studies available for thalidomide and Delayed Hypersensitivity
| Article | Year |
|---|---|
Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Topics: Aged; Biomarkers; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitiv | 2019 |
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Topics: Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Immu | 2014 |
Serum macrophage migration inhibition activity in patients with leprosy.
Topics: Dapsone; Dinitrochlorobenzene; Humans; Hypersensitivity, Delayed; Leprosy; Macrophage Migration-Inhi | 1982 |
Enhancement of antibody response and delayed-type hypersensitivity by thalidomide in mice.
Topics: Animals; Antibody Formation; Female; Hypersensitivity, Delayed; Male; Mice; Organ Size; Thalidomide | 1988 |